Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPhA’s Drug Shortage Initiative Clears FTC Hurdle; Still Working With FDA

This article was originally published in The Gold Sheet

Executive Summary

Five manufacturers have agreed to give IMS Health production and supply information about drugs in short supply; GPhA and IMS are working with FDA to finalize the details of the accelerated recovery initiative.

You may also be interested in...



Drug Shortage Prevention Could Be Funded Through GDUFA

GPhA recommends FDA deploy user fee research money to look at shortage risk assessment and mitigation strategies, while the trade group continues to look for a product to fit its own shortage prediction model.

Generic Rx Shortage Initiative Stuck: Too Few Manufacturers To Pick Up Slack

The heavily concentrated sterile injectable manufacturing industry is creating roadblocks to the success of the Accelerated Recovery Initiative; GPhA predicts crisis will linger for years to come.

EU and U.S. Developing New Approaches to Prevent Drug Shortages

A UK MHRA official said there is a “regulatory dilemma” between meeting GMP enforcement obligations and preventing drug shortages. New changes in the EU GMP Guide aim to take a more proactive approach to drug shortages by requiring early notification by manufacturers, while in the U.S. a new drug shortage prevention program called the Accelerated Recovery Initiative (ARI) is finally getting off the ground.

Related Content

Related Companies

UsernamePublicRestriction

Register

PS000703

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel